Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker SPRO · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilast… NCT06059846 · Urinary Tract Infection, Acute Pyelonephritis TBP-PI-HBr, Imipenem-cilastatin | SPRO Spero Therapeutics | Phase 3 | Completed | 1,690 | Jan 27, 2025 | Registry ↗ |
| Oct 9, 2025 | A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared… NCT05496374 · Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Placebo, SPR720 500 mg | SPRO Spero Therapeutics | Phase 2 | Completed | 25 | Oct 8, 2024 | Registry ↗ |
| May 20, 2025 | A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (… NCT06727136 · Healthy Participants TBP-PI-HBr | SPRO Spero Therapeutics | Phase 1 | Completed | 39 | Apr 22, 2025 | Registry ↗ |
| Apr 15, 2024 | Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function NCT04865393 · Renal Impairment SPR206 | SPRO Spero Therapeutics | Phase 1 | Completed | 37 | Dec 1, 2021 | Registry ↗ |
| Mar 27, 2024 | A Study to Compare Two Bioanalytical Assays for Tebipenem NCT05856747 · Healthy Volunteers TBP-PI-HBr | SPRO Spero Therapeutics | Phase 1 | Completed | 20 | Jun 1, 2023 | Registry ↗ |
| Mar 7, 2024 | A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epith… NCT05955586 · Healthy Volunteer SPR720 | SPRO Spero Therapeutics | Phase 1 | Completed | 33 | Feb 9, 2024 | Registry ↗ |
| Mar 4, 2024 | A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin… NCT05966688 · Healthy Volunteers SPR720, Azithromycin | SPRO Spero Therapeutics | Phase 1 | Completed | 39 | Jan 30, 2024 | Registry ↗ |
| Jul 25, 2022 | Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil… NCT03788967 · Complicated Urinary Tract Infection, Acute Pyelonephritis TBPM-PI-HBr, Ertapenem | SPRO Spero Therapeutics | Phase 3 | Completed | 1,372 | May 20, 2020 | Registry ↗ |
| Feb 28, 2022 | Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With My… NCT04553406 · Mycobacterium Avium Complex, Non-tuberculous Mycobacterium… SPR720, Placebo | SPRO Spero Therapeutics | Phase 2 | Terminated | 2 | Jan 28, 2021 | Registry ↗ |
| Nov 17, 2021 | Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers NCT04868292 · Healthy Volunteers SPR206 | SPRO Spero Therapeutics | Phase 1 | Completed | 34 | Sep 16, 2021 | Registry ↗ |
| May 4, 2021 | Effect of Tebipenem on Normal Human Intestinal Microbiota NCT04376554 · Healthy Volunteers TBPM-PI-HBr, amoxicillin-clavulanate | SPRO Spero Therapeutics | Phase 1 | Completed | 30 | Apr 6, 2021 | Registry ↗ |
| Mar 16, 2021 | Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial L… NCT04710407 · Healthy Volunteers TBPM-PI-HBr | SPRO Spero Therapeutics | Phase 1 | Completed | 30 | Mar 10, 2021 | Registry ↗ |
| Nov 27, 2020 | Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Var… NCT04178577 · Renal Impairment Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) | SPRO Spero Therapeutics | Phase 1 | Completed | 39 | Sep 6, 2020 | Registry ↗ |
| Nov 12, 2020 | Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI… NCT04625855 · Healthy Volunteers TBPM-PI-HBr | SPRO Spero Therapeutics | Phase 1 | Completed | 8 | Oct 16, 2020 | Registry ↗ |
| Sep 4, 2020 | Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipe… NCT04368585 · Healthy Volunteers Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminu… | SPRO Spero Therapeutics | Phase 1 | Completed | 20 | Aug 8, 2020 | Registry ↗ |
| Aug 12, 2020 | Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-H… NCT04421885 · Healthy Volunteers Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference, T… | SPRO Spero Therapeutics | Phase 1 | Completed | 36 | Jul 11, 2020 | Registry ↗ |
| Mar 13, 2020 | A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluati… NCT04238195 · TQT Study Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Mox… | SPRO Spero Therapeutics | Phase 1 | Completed | 24 | Feb 26, 2020 | Registry ↗ |
| Jan 10, 2020 | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Hea… NCT03792308 · Healthy Volunteers SPR206, Placebo | SPRO Spero Therapeutics | Phase 1 | Completed | 94 | Dec 23, 2019 | Registry ↗ |
| Oct 28, 2019 | A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers NCT03796910 · Healthy Volunteers SPR720 for SAD, Placebo for SAD | SPRO Spero Therapeutics | Phase 1 | Completed | 96 | Sep 24, 2019 | Registry ↗ |
| Aug 28, 2018 | Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 NCT03395249 · Healthy Volunteers SPR994, Placebo Oral Tablet | SPRO Spero Therapeutics | Phase 1 | Completed | 124 | Aug 2, 2018 | Registry ↗ |
| Jan 5, 2018 | Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 NCT03376529 · Healthy Volunteers SPR741, Ceftazidime | SPRO Spero Therapeutics | Phase 1 | Completed | 27 | Dec 19, 2017 | Registry ↗ |
| Oct 5, 2017 | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Hea… NCT03022175 · Healthy Volunteers SPR741, Placebo | SPRO Spero Therapeutics | Phase 1 | Completed | 64 | Jul 2017 | Registry ↗ |
22 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances